<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05060588</url>
  </required_header>
  <id_info>
    <org_study_id>Sacu-HPT</org_study_id>
    <nct_id>NCT05060588</nct_id>
  </id_info>
  <brief_title>Sacubitril/Valsartan Versus Valsartan for Hypertensive Patients With Acute Myocardial Infarction</brief_title>
  <official_title>The Effect of Sacubitril/Valsartan Versus Valsartan on the Short-term Prognosis of Hypertensive Patients With Acute Myocardial Infarction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qingdao Central Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qingdao Central Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Studies have demonstrated that the early initiation of ACEI/ARB to patients with acute&#xD;
      myocardial infarction is beneficial, especially in patients combined with reduced LVEF or&#xD;
      mild-moderate heart failure. Therefore, ACEI/ARB is a traditional treatment for patients&#xD;
      post-infarction. Recent clinical trials have demonstrated that Sacubitril/Valsartan is more&#xD;
      beneficial than Ramipril to patients post-PCI.Besides, Sacubitril/Valsartan is also effective&#xD;
      for essential hypertension.This study aims to assess the effect of Sacubitril/Valsartan on&#xD;
      short-term prognosis in hypertensive patients with acute myocardial infarction compared&#xD;
      against Valsartan.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">February 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of MACE events no.1 by phone calls and questionnaires</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the rate of myocardial infarction in post-infarction patients during the study follow-up.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of MACE events No.2 by phone calls and questionnaires</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the rate of stroke in patients post-MI during the follow up period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of MACE events No.3 phone calls and questionnaires</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the rate of death from cardiovascular causes during the follow up time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Left ventricular ejection fraction(LVEF) by echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate baseline left ventricular ejection fraction (LVEF)in post-infarct patients and 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of post infarction angina by following up in the clinic</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the Effect of Sacubitril/Valsartan versus Valsartan on the development of post-infarction angina.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of heart failure occurrence by following up in the clinic</measure>
    <time_frame>6 months</time_frame>
    <description>Assess the occurence of heart failure during the study follow-up.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Left ventricular end-diastolic volume(LVEDV) by echocardiography</measure>
    <time_frame>6 months</time_frame>
    <description>Evaluate the baseline LVEDV in post-infarct patients and 6 months of treatment using echocardiography</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Myocardial Infarction</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Sacubitril/Valsartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Valsartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 tablet of Valsartan every 24 hours for 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril/Valsartan 49/51mg/Tab</intervention_name>
    <description>patients who meet the inclusion criteria are randomized to receive Sacubitril/Valsartan 24/26 mg once every 12 hours for 6 months</description>
    <arm_group_label>Sacubitril/Valsartan</arm_group_label>
    <other_name>Sacubitril/Valsartan Group</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Valsartan 80mg/Tab</intervention_name>
    <description>Patients who meet the inclusion criteria are randomized to receive valsartan one tablet every 24 hours for 6 months.</description>
    <arm_group_label>Valsartan</arm_group_label>
    <other_name>Valsartan Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Diagnosed with new-onset MI, either STEMI or NSTEMI, according to the fourth universal&#xD;
             definition of MI (Thygesen et al. 2019), disease onset within 7 days.&#xD;
&#xD;
          2. Patients are previously diagnosed with essential hypertension or newly diagnosed with&#xD;
             essential hypertension.&#xD;
&#xD;
          3. Capable of giving signed informed consent, which includes compliance with the&#xD;
             requirements and restrictions listed in the informed consent form (ICF) and the&#xD;
             protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with severe renal dysfunction. (GFR&lt;60mmol/L).&#xD;
&#xD;
          2. Patients who have recently undergone immunosuppressive therapy.&#xD;
&#xD;
          3. Patients who are known to be allergic to Sacubitril/Valsartan and Valsartan.&#xD;
&#xD;
          4. Patients who are hemodynamically unstable.&#xD;
&#xD;
          5. Chronic symptomatic heart failure within the last year and known reduced ejection&#xD;
             fraction (LVEF≤40 %).&#xD;
&#xD;
          6. Severe hepatic impairment (Child-Pugh class C) at the time of inclusion into the&#xD;
             trial.&#xD;
&#xD;
          7. Any non-CV condition, such as active malignancy requiring treatment at the time of&#xD;
             screening, or severe diseases with a life expectancy of fewer than two years based on&#xD;
             the investigator´s clinical judgment.&#xD;
&#xD;
          8. Currently on treatment with Sacubitril/Valsartan or an ACEI/ARB.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Teng, MD</last_name>
    <role>Study Director</role>
    <affiliation>Qingdao Central Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mengmei Li, MD</last_name>
    <phone>0086053284961672</phone>
    <email>sjogen@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Mengmei Li</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <zip>266042</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jun Teng, MD</last_name>
      <phone>0086053284961819</phone>
      <email>owen-145@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 13, 2021</study_first_submitted>
  <study_first_submitted_qc>September 18, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 29, 2021</study_first_posted>
  <last_update_submitted>September 18, 2021</last_update_submitted>
  <last_update_submitted_qc>September 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Sacubitril/Valsartan</keyword>
  <keyword>Valsartan</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>Hypertension</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

